読み込み中
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
前日終値
$25.70
+$1.10 · +4.47%
日中の時刻はETです。市場データは遅延する場合があります。
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
日中レンジ
現在 $25.70
52週レンジ
現在 $25.70
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
56
適正価値
センチメント
67
強気
リスク
56
やや高いリスク
モメンタム
64
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
日中レンジ
現在 $25.70
52週レンジ
現在 $25.70
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.4億 USD | 6351.8万 USD | 3.78億 USD | 6092万 USD | 5184.4万 USD |
| 売上原価 | 2229.4万 USD | 3.68億 USD | — | 3.12億 USD | 2.32億 USD |
| 粗利益 | 1.17億 USD | −3.04億 USD | 3.78億 USD | −2.51億 USD | −1.8億 USD |
| 研究開発 | 4.1億 USD | 3.68億 USD | 4.37億 USD | 3.12億 USD | 3.87億 USD |
| 販売・一般管理 | 1.14億 USD | 1.12億 USD | 1.17億 USD | 8780.5万 USD | 5722.2万 USD |
| 営業費用 | 5.01億 USD | 1.12億 USD | 5.54億 USD | 8780.5万 USD | 2.12億 USD |
| 受取利息 | — | 4909.4万 USD | 4667.6万 USD | 1529.7万 USD | — |
| 支払利息 | 4373.3万 USD | — | — | — | — |
| 減価償却費と償却費 | 2229.4万 USD | 2192.5万 USD | 2001.2万 USD | 1414.7万 USD | 745.1万 USD |
| 営業利益 | −3.84億 USD | −4.16億 USD | −1.76億 USD | −3.38億 USD | −3.92億 USD |
| 純利益 | −7999.2万 USD | −3.77億 USD | −1.33億 USD | −2.89億 USD | −3.71億 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$59.50
上昇余地（131.52%）この株式へのエクスポージャーを報告している上場投資信託です。
ARK Innovation ETFARKK1.56億2.27%55.62億 USD0.75%$89.62+2.31%
Vanguard Morningstar Total Stock Market ETFVTI9659.53万0.00%2.3兆 USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI8579.5万0.87%98.74億 USD0.35%$153.77+3.00%
Vanguard Morningstar Small-Cap ETFVB6961.99万0.04%1853億 USD0.03%$289.48+0.64%
ARK Genomic Revolution ETFARKG6634.51万3.24%15.57億 USD0.75%$51.30+4.08%
iShares Russell 2000 ETFIWM6426.34万0.08%782.66億 USD0.19%$278.94+0.49%
Vanguard Morningstar Small-Cap Growth ETFVBK4010.45万0.09%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF3408.01万0.03%954億 USD0.05%$235+0.80%ARK Innovation ETFARKKVanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap ETFVBARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
